Keyphrases
Open Globe Injury
92%
Triamcinolone Acetonide
78%
Bevacizumab
75%
Intravitreal
67%
Corneal Endothelial Cells
61%
Retinal Ganglion Cell Loss
61%
Injury Model
61%
Resveratrol
61%
Ischemia-reperfusion Injury
61%
Conjunctival Autograft
61%
Conjunctival
61%
Platelet-rich Fibrin Membrane
61%
Treatment Group
58%
Endothelial Cell Density
43%
Phacoemulsification
43%
Type I Collagen
42%
Collagen Expression
42%
Inflammation
41%
Diabetic Retinopathy
41%
Rabbit Eye
37%
Proliferative Vitreoretinopathy
37%
Caspase-3 Expression
37%
Retinal Ganglion Cells
35%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
33%
Wound Healing
33%
Corticosteroids
33%
Intraocular Pressure
30%
Intravitreal Ranibizumab
30%
Structural Recovery
30%
Limbal Stem Cells
30%
Intracameral Injection
30%
Intravitreal Administration
30%
Eye Health
30%
Peripheral Arterial Stiffness
30%
Diabetic Macular Edema
30%
Intravitreal Triamcinolone Acetonide Injection
30%
MicroRNA
30%
Type 2 Diabetes Mellitus (T2DM)
30%
Na +
30%
Neuroprotective Agents
30%
Collagen Type 1
30%
Collagen Type I
30%
Penetrating Injury
30%
Matrix Metalloproteinases
30%
Hypothermic Perfusion
30%
Renal Impairment
30%
Mean Platelet Volume
30%
Platelet Distribution Width
30%
Transforming Growth Factor-β
30%
Plasminogen Activator inhibitor-1 (PAI-1)
30%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Triamcinolone Acetonide
95%
Bevacizumab
95%
Diabetic Retinopathy
82%
Reperfusion Injury
61%
Resveratrol
61%
Rat Model
61%
Muskmelon
61%
Gliadin
61%
Superoxide Dismutase
61%
Leporidae
60%
Intravitreal Administration
52%
Hyperglycemia
51%
Tumor Necrosis Factor
49%
Proliferative Diabetic Retinopathy
41%
New Zealand Rabbit
40%
Vitreoretinopathy
39%
Treatment Group
38%
Inflammation
38%
Neuroprotective Agent
37%
Diabetic Macular Edema
35%
Transforming Growth Factor Beta
35%
Dexamethasone
33%
Antioxidant
33%
Penetrating Trauma
30%
Antiapoptotic
30%
microRNA
30%
Matrix Metalloproteinase
30%
Plasminogen Activator Inhibitor 1
30%
microRNA 126
30%
Collagen Type 1
30%
Platelet-Rich Fibrin
30%
Experimental Animal
30%
Central Retina Artery Occlusion
30%
Interleukin 4
30%
Strabismus
30%
Asiatic Acid
30%
Open Angle Glaucoma
30%
Caspase 3
27%
Wound Healing
23%
Reactive Oxygen Metabolite
23%
Diseases
21%
Gelatinase A
20%
Tissue Inhibitor of Metalloproteinase
20%
Glaucoma Medication
20%
Diabetes Mellitus
20%
Phosphate Buffered Saline
18%
Retina Macula Cystoid Edema
15%
Eye Injury
14%
Glaucoma
14%
Medicine and Dentistry
Treatment Group
64%
Bevacizumab
61%
Triamcinolone Acetonide
61%
Collagen Type 1
61%
Autograft
61%
Platelet-Rich Fibrin
61%
Diabetic Retinopathy
59%
Cell Density
56%
Endothelial Cell
51%
Tumor Necrosis Factor
49%
Caspase 3
45%
Phacoemulsification
41%
Ganglion
35%
Wound Healing
30%
Penetrating Trauma
30%
Platelet
30%
Cell Loss
30%
Sodium Ion
30%
Endothelium Cell
30%
Adenosine Triphosphatase (Potassium)
30%
Matrix Metalloproteinase
30%
Mean Platelet Volume
30%
Arterial Stiffness
30%
Reperfusion Injury
30%
Corneal Endothelium
30%
Mesenchymal Stem Cell
30%
Maturity Onset Diabetes of the Young
30%
Resveratrol
30%
Antiapoptotic
30%
Intraocular Pressure
30%
Glutathione Reductase
30%
Central Retinal Artery Occlusion
30%
Superoxide Dismutase
30%
Interleukin-1
30%
Gliadin
30%
Interleukin 4
30%
Cell Count
30%
Coats' Disease
30%
Strabismus Surgery
30%
Asiatic Acid
30%
Eosinophil
30%
Dexamethasone
30%
Hyperglycemia
24%
Balanced Salt Solution
21%
Gelatinase A
20%
Metalloprotease Inhibitor
20%
Retinal Telangiectasia
20%
Intravitreal Administration
18%
Phosphate Buffered Saline
18%
Vasculotropin
18%